Sugi Predict

Sugi Predict / Compounds / SCHEMBL189207

SCHEMBL189207

SCHEMBL189207

COC(=O)c1ccc(B(O)O)cc1OC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.46
▸ GAA P10253 3/20 0.45
▸ CA1 P00915 2/20 0.43
▸ CA2 P00918 2/20 0.43
▸ CA12 O43570 1/20 0.43
▸ CA7 P43166 1/20 0.43
▸ PDK2 Q15119 1/20 0.43
▸ PDK4 Q16654 1/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ CA14 Q9ULX7 1/20 0.43
▸ POLB P06746 1/20 0.42
▸ CHEK1 O14757 1/20 0.42
▸ ENPP2 Q13822 2/20 0.41
▸ HSD17B10 Q99714 3/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ GLA P06280 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ CASP1 P29466 1/20 0.41
▸ CASP7 P55210 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17464347 0.86 KDM4E (0.46) KDM4EGAACA1CA2POLB
SCHEMBL425149 0.84 ALDH1A1 (0.59) KDM4ECA1CA2CA12CA7
SCHEMBL29955104 0.84 ALDH1A1 (0.59) KDM4ECA1CA2CA12CA7
SCHEMBL5058938 0.84 HSD17B2 (0.47) KDM4EGAACA1CA2CA12
SCHEMBL29955699 0.84 HSD17B2 (0.47) KDM4EGAACA1CA2CA12
SCHEMBL9110483 0.84 CA1 (0.47) KDM4EGAACA1CA2CA12
SCHEMBL2562408 0.83 CFTR (0.42) KDM4EGAACA1CA2CA12
SCHEMBL30016565 0.83 MKNK1 (0.48) KDM4EGAACA1CA2CHEK1
SCHEMBL9108508 0.81 CA12 (0.62) KDM4EGAACA1CA2CA12
SCHEMBL29492895 0.81 KDM4E (0.46) KDM4EGAACA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122036736-A Pyrrolo [2,3-d ] pyrimidine derivative, synthetic method and application 云南大学 2026-05-15 — — CN claimed
CN-119638706-A Indolo [3,2,1-JK ] carbazole main body stability assembly transmission material and preparation method thereof, perovskite solar cell and preparation method thereof 广东工业大学 2025-03-18 — — CN claimed
CN-115959993-B Synthesis method of 2-aryl propionic acid compound 山东中医药大学 2025-01-07 — — CN claimed
CN-115959993-A Synthetic method of 2-aryl propionic acid compound 山东中医药大学 2023-04-14 — — CN claimed
EP-4743081-A1 MODULATORS OF MITOCHONDRIAL DNA REPLICATION Pretzel Therapeutics, Inc. (US) 2026-05-20 — — EP disclosed
CN-122036736-A Pyrrolo [2,3-d ] pyrimidine derivative, synthetic method and application 云南大学 2026-05-15 — — CN disclosed
US-12576055-B2 Disease detection and treatment based on trimethyl-lysine levels THE CLEVELAND CLINIC FOUNDATION (US) 2026-03-17 — — US disclosed
US-20260034140-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LTD (GB) 2026-02-05 — — US disclosed
US-12453734-B2 Modulators of rho-associated protein kinase REDX PHARMA LIMITED (GB) 2025-10-28 — — US disclosed
US-12384778-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2025-08-12 — — US disclosed
EP-3321268-B1 BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF AGENCY SCIENCE TECH & RES (SG) 2025-06-04 — — EP disclosed
CN-119638706-A Indolo [3,2,1-JK ] carbazole main body stability assembly transmission material and preparation method thereof, perovskite solar cell and preparation method thereof 广东工业大学 2025-03-18 — — CN disclosed
US-20060100252-A1 Aminoalcohol derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2006-05-11 — — US disclosed
US-7037938-B2 Aminoalcohol derivatives ASTELLAS PHARMA INC. (JP) 2006-05-02 — — US disclosed
EP-1546086-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-06-29 — — EP disclosed
US-20050090669-A1 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists ASTELLAS PHARMA INC. (JP) 2005-04-28 — — US disclosed
EP-1483236-A1 AMINOALCOHOL DERIVATIVES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-08 — — EP disclosed
US-20040006143-A1 For therapy of urinary incontinence FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-01-08 — — US disclosed
WO-2004002939-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-01-08 — — WO disclosed
WO-2003076397-A1 AMINOALCOHOL DERIVATIVES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12384778-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 KDM4E 3818/4885GAA 762/4885CA1 4305/4885
US-20260034140-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK1, ROCK2, RHOA KDM4E 1773/4885GAA 4212/4885CA1 3571/4885
US-12453734-B2 Modulators of rho-associated protein kinase ROCK2, ROCK1, RHOA KDM4E 1568/4885GAA 2236/4885CA1 4161/4885
US-12576055-B2 Disease detection and treatment based on trimethyl-lysine levels BHMT, BHMT2, EHMT2 KDM4E 270/4885GAA 3715/4885CA1 2402/4885
US-20060100252-A1 Aminoalcohol derivatives H1-0, CHRM2, CHRM1 KDM4E 2289/4885GAA 3421/4885CA1 2409/4885
US-20040006143-A1 For therapy of urinary incontinence H1-0, HRH2, H1-2 KDM4E 1554/4885GAA 3352/4885CA1 557/4885
US-20050090669-A1 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists ADRB2, ADRB1, ADRB3 KDM4E 1833/4885GAA 4520/4885CA1 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.